Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells
Volume 11, Issue 19
Purchase or Subscribe
October 1, 2012
Pages 3649 - 3655http://dx.doi.org/10.4161/cc.21926
: Wee1, apoptosis, cancer, heat shock protein 90, molecular targeted anticancer drugs
Authors: Aki Iwai, Dimitra Bourboulia, Mehdi Mollapour, Sandra Jensen-Taubman, Sunmin Lee, Alison C. Donnelly, Soichiro Yoshida, Naoto Miyajima, Shinji Tsutsumi, Armine K. Smith, David Sun, Xiaolin Wu, Brian S. Blagg, Jane B. Trepel, William G. Stetler-Stevenson and Len Neckers View affiliations
Heat shock protein 90 (Hsp90) is an essential, evolutionarily conserved molecular chaperone. Cancer cells rely on Hsp90 to chaperone mutated and/or activated oncoproteins, and its involvement in numerous signaling pathways makes it an attractive target for drug development. Surprisingly, however, the impact of Hsp90 inhibitors on cancer cells is frequently cytostatic in nature, and efforts to enhance the antitumor activity of Hsp90 inhibitors in the clinic remain a significant challenge. In agreement with previous data obtained using Wee1 siRNA, we show that dual pharmacologic inhibition of Wee1 tyrosine kinase and Hsp90 causes cancer cells to undergo apoptosis in vitro and in vivo. Gene expression profiling revealed that induction of the intrinsic apoptotic pathway by this drug combination coincided with transcriptional downregulation of Survivin and Wee1, an outcome not seen in cells treated separately with either agent. At the translational level, expression of these two proteins, as well as activated Akt, was completely abrogated. These data support the hypothesis that Wee1 inhibition sensitizes cancer cells to Hsp90 inhibitors; they establish combined Wee1/Hsp90 inhibition as a novel therapeutic strategy; and they provide a mechanistic rationale for enhancing the pro-apoptotic activity of Hsp90 inhibitors.
Received: August 16, 2012; Accepted: August 22, 2012; Published Online: August 30, 2012
Full Text - Ahead of Print Available - Log in!